Neuromuscular Blocking Agents

Neuromuscular blocking agents (NMBAs) are skeletal muscle relaxants used to facilitate tracheal intubation, provide surgical relaxation, and aid mechanical ventilation. They act at the nicotinic (N_M) receptor of the neuromuscular junction (NMJ) and are a perennial NEET PG favourite for their pharmacology, the dramatic adverse effect of malignant hyperthermia, and the elegant logic of reversal agents.

The neuromuscular junction — quick refresher

Acetylcholine (ACh) is synthesised in the motor nerve terminal, stored in vesicles, and released on depolarisation. It crosses the cleft and binds the two alpha-subunits of the postsynaptic nicotinic (N_M) receptor — a ligand-gated cation channel. Binding of two ACh molecules opens the channel, Na⁺ enters, an end-plate potential (EPP) is generated, and if threshold is reached a propagated muscle action potential triggers contraction. ACh is then rapidly hydrolysed by acetylcholinesterase (AChE) in the synaptic cleft.

High-yield: Both alpha-subunits must be occupied to open the receptor. NMBAs exploit this — a non-depolariser needs to block only one of the two sites to prevent opening, which is why competitive blockers are effective.

NMBAs do not cross the blood–brain barrier (quaternary ammonium, highly ionised) — so a paralysed patient is fully aware and feels pain unless separately anaesthetised. This is the basis of the dreaded "awareness under anaesthesia."

Classification

NMBAs are divided by mechanism into depolarising and non-depolarising (competitive) blockers. Non-depolarisers are further classed by chemistry (aminosteroid vs benzylisoquinolinium) and by duration.

Class	Examples	Mechanism
Depolarising	Succinylcholine (suxamethonium), Decamethonium	Persistent N_M agonist → sustained depolarisation
Non-depolarising — aminosteroid	Pancuronium, Vecuronium, Rocuronium, Pipecuronium	Competitive antagonist at N_M
Non-depolarising — benzylisoquinolinium	d-Tubocurarine, Atracurium, Cisatracurium, Mivacurium, Doxacurium	Competitive antagonist; tend to release histamine

A useful duration-based grouping of non-depolarisers:

Duration	Agent(s)	Approx clinical duration
Ultra-short	Mivacurium	12–18 min
Short–intermediate	Atracurium, Cisatracurium, Vecuronium, Rocuronium	30–45 min
Long	Pancuronium, Pipecuronium, d-Tubocurarine, Doxacurium	60–120 min

High-yield: "-curium / -curonium" hints at the chemistry — aminosteroids end in "-curonium/-onium" (vecuronium, rocuronium, pancuronium); benzylisoquinoliniums end in "-curium" (atracurium, cisatracurium, mivacurium) plus tubocurarine.

Depolarising block — succinylcholine

Succinylcholine = two ACh molecules joined back-to-back. It binds N_M and opens the channel, but unlike ACh it is not hydrolysed by AChE; instead it is metabolised slowly by plasma pseudocholinesterase (butyrylcholinesterase). Persistent agonism keeps the membrane depolarised so that adjacent membrane cannot repolarise → voltage-gated Na⁺ channels stay inactivated → no further action potential → flaccid paralysis.

Onset of action flow: IV succinylcholine → transient muscle fasciculations (disorganised depolarisation) → flaccid paralysis within 30–60 seconds → recovery in 5–10 minutes as the drug diffuses away and is hydrolysed.

High-yield: Succinylcholine has the fastest onset and shortest duration of all NMBAs — the agent of choice for rapid sequence intubation (RSI) and for short procedures (e.g., ECT, laryngospasm). Standard intubating dose ≈ 1–1.5 mg/kg.

Phase I vs Phase II block

With repeated dosing or prolonged infusion, the character of the depolarising block can change:

Feature	Phase I (depolarising)	Phase II (desensitising)
Mechanism	Sustained depolarisation	Receptor desensitisation, resembles non-depolarising block
Response to TOF / tetanus	No fade; sustained	Fade present
Post-tetanic potentiation	Absent	Present
Effect of anticholinesterase (neostigmine)	Augments block (worse)	Reverses block
Onset	Initial	After large/repeated doses

High-yield: Neostigmine worsens a Phase I block but reverses a Phase II block — a classic exam discriminator.

Pseudocholinesterase deficiency → prolonged apnoea

Succinylcholine's short action depends on plasma pseudocholinesterase. In patients with atypical (genetically variant) pseudocholinesterase or acquired enzyme deficiency (liver disease, pregnancy, malnutrition), metabolism is slow → prolonged neuromuscular paralysis / apnoea lasting hours.

• The dibucaine number quantifies enzyme quality: dibucaine inhibits normal enzyme by ~80% (dibucaine number ≈ 80), but inhibits the atypical enzyme only by ~20% (dibucaine number ≈ 20). Heterozygotes ≈ 40–60.
• Management of prolonged apnoea: continue mechanical ventilation and sedation until spontaneous recovery; it is self-limiting. Do not give neostigmine routinely.

High-yield: Low dibucaine number = atypical enzyme = prolonged succinylcholine apnoea. The dibucaine number reflects the quality (genotype) of the enzyme, not the quantity.

Other adverse effects of succinylcholine

• Hyperkalaemia — normally ~0.5 mEq/L rise; exaggerated and potentially fatal in burns, crush injury, denervation/spinal cord injury, prolonged immobilisation, Guillain–Barré (upregulation of extrajunctional/foetal receptors). Avoid succinylcholine in these.
• Malignant hyperthermia (see below).
• Bradycardia / arrhythmias — muscarinic stimulation at SA node, especially with repeat doses or in children; pretreat with atropine.
• Increased intragastric, intracranial, and intraocular pressure — caution in open-globe eye injury and raised ICP.
• Myalgia — post-operative muscle pain from fasciculations.
• Masseter spasm / trismus — may herald malignant hyperthermia.

High-yield: Succinylcholine is contraindicated in major burns and crush/denervation injury because of life-threatening hyperkalaemic cardiac arrest (typically after the first 24–48 h once receptor upregulation occurs).

Malignant hyperthermia (MH)

A pharmacogenetic emergency triggered by succinylcholine and volatile anaesthetics (halothane, sevoflurane, isoflurane, desflurane).

• Genetics: autosomal dominant; mutation in the ryanodine receptor (RYR1) gene on chromosome 19 (also CACNA1S).
• Pathophysiology: uncontrolled Ca²⁺ release from the sarcoplasmic reticulum → sustained muscle contraction, hypermetabolism, ATP depletion, heat generation.
• Clinical features: earliest reliable sign is a rising end-tidal CO₂ (ETCO₂); masseter/generalised muscle rigidity, tachycardia, hyperthermia (a late sign), mixed acidosis, hyperkalaemia, rhabdomyolysis (myoglobinuria), arrhythmias.
• Drug of choice: Dantrolene (IV 2.5 mg/kg, repeat to max ~10 mg/kg) — blocks the ryanodine receptor and reduces Ca²⁺ release. Plus: stop trigger, hyperventilate with 100% O₂, active cooling, treat hyperkalaemia and acidosis.
• Confirmatory test: caffeine–halothane contracture test on muscle biopsy (gold standard).

High-yield: MH = RYR1 mutation; trigger = succinylcholine + volatile agents; treat with DANTROLENE. Earliest sign = unexplained rise in ETCO₂.

Mnemonic for MH triggers — "Succinylcholine + volatiles." Safe ("trigger-free") agents include propofol, nitrous oxide, opioids, benzodiazepines, and all non-depolarising NMBAs.

Non-depolarising (competitive) blockers

These competitively antagonise ACh at N_M — no fasciculations, gradual onset of flaccid paralysis. Because the block is competitive, it is surmountable: raising synaptic ACh (via anticholinesterases) reverses it. Small muscles (eyes, fingers) are affected first; the diaphragm is last to be paralysed and first to recover.

Characteristic features (the "fade" signs)

• Fade on train-of-four (TOF) and tetanic stimulation.
• Post-tetanic potentiation present.
• Block potentiated by inhalational anaesthetics, aminoglycosides, hypothermia, hypokalaemia, hypermagnesaemia (e.g., eclampsia therapy), and acidosis.
• Block antagonised / reversed by neostigmine.

Agent-specific pearls

• Atracurium — undergoes Hofmann elimination (spontaneous, non-enzymatic degradation at body pH/temperature) plus ester hydrolysis → organ-independent, ideal in hepatic and renal failure. Metabolite laudanosine can cause CNS excitation/seizures in high doses. Releases histamine.
• Cisatracurium — isomer of atracurium; relies almost entirely on Hofmann elimination, produces less laudanosine, and causes minimal histamine release. Preferred in critically ill / organ failure.
• Vecuronium — aminosteroid, hepatic metabolism/biliary excretion, cardiovascularly stable, no histamine release.
• Rocuronium — fastest onset among non-depolarisers; at high dose (1.2 mg/kg) gives intubating conditions in ~60 s, making it the non-depolarising alternative for RSI when succinylcholine is contraindicated. Reversed rapidly by sugammadex.
• Pancuronium — long-acting; vagolytic → tachycardia and hypertension; renal excretion.
• Mivacurium — only non-depolariser metabolised by plasma pseudocholinesterase (so also prolonged in pseudocholinesterase deficiency); shortest acting.
• d-Tubocurarine — prototype; marked histamine release and ganglion blockade → hypotension; largely historical.

High-yield: Atracurium and cisatracurium are the drugs of choice in hepatic/renal failure because of Hofmann elimination (organ-independent metabolism).

Reversal of neuromuscular blockade

Anticholinesterases

Neostigmine is the classic reversal agent for non-depolarising block. It inhibits AChE → accumulated ACh outcompetes the blocker at N_M.

Reversal flow: Neostigmine → ↑ synaptic ACh → but ACh also floods muscarinic receptors → bradycardia, salivation, miosis, bronchospasm. Therefore neostigmine is always co-administered with an antimuscarinic — glycopyrrolate (preferred; matched onset) or atropine.

High-yield: Neostigmine + glycopyrrolate is the standard reversal combination. Neostigmine alone causes dangerous bradycardia. Neostigmine cannot reverse a deep block — there must be some spontaneous recovery (e.g., TOF count ≥ 2–4) for it to work.

Sugammadex

A modified gamma-cyclodextrin that encapsulates aminosteroid relaxants (chelates rocuronium > vecuronium) and removes them from the plasma and NMJ.

• Reverses even profound/deep block rapidly, including immediately after a high-dose rocuronium "can't intubate, can't ventilate" RSI scenario.
• Does not work on benzylisoquinoliniums (atracurium/cisatracurium) and is ineffective for succinylcholine.
• No muscarinic effects → no need for an antimuscarinic.

High-yield: Sugammadex reverses rocuronium and vecuronium (aminosteroids); it does NOT reverse atracurium, cisatracurium, or succinylcholine.

Monitoring — Train-of-Four (TOF)

A peripheral nerve stimulator delivers four supramaximal stimuli at 2 Hz over 2 seconds, and the TOF ratio = amplitude of the 4th twitch ÷ amplitude of the 1st twitch (T4/T1).

Pattern	Interpretation
All 4 twitches equal, no fade	No / negligible block (or depolarising Phase I)
Progressive fade (T4 < T1)	Non-depolarising (competitive) block, or Phase II
TOF ratio > 0.9	Adequate recovery — safe to extubate
Loss of twitches sequentially (4→3→2→1→0)	Deepening block; loss of 4th first

High-yield: A TOF ratio > 0.9 indicates adequate reversal for safe extubation. Fade is the signature of non-depolarising and Phase II blockade and is absent in pure depolarising (Phase I) block.

Other monitoring modes: post-tetanic count (PTC) for deep block when TOF count = 0, and double-burst stimulation to detect residual fade clinically.

Drug interactions worth remembering

• Aminoglycosides, tetracyclines, polymyxins → potentiate non-depolarising block (decrease ACh release / membrane effects).
• Calcium channel blockers, magnesium → potentiate block (relevant in eclampsia patients on MgSO₄).
• Inhalational anaesthetics → potentiate; reduce NMBA dose.
• Hypokalaemia, hypothermia, acidosis → prolong block.
• Chronic phenytoin/carbamazepine → resistance to non-depolarisers (hepatic enzyme induction / receptor upregulation).

Complications

• Residual paralysis / post-operative weakness (TOF < 0.9) → hypoventilation, aspiration risk.
• Anaphylaxis — NMBAs (esp. succinylcholine and rocuronium) are a leading cause of peri-operative anaphylaxis.
• Critical-illness myopathy with prolonged ICU NMBA + steroid use (esp. aminosteroids like vecuronium).
• Awareness under anaesthesia if relaxant given without adequate hypnosis.
• Succinylcholine-specific: hyperkalaemic arrest, MH, prolonged apnoea, myalgia, raised IOP/ICP.

Key differentials & discriminators

• Depolarising vs non-depolarising block: fasciculations (depol only), fade (non-depol), effect of neostigmine (augments Phase I, reverses non-depol), post-tetanic potentiation (non-depol only).
• Prolonged apnoea after surgery: think pseudocholinesterase deficiency (succinylcholine/mivacurium) → check dibucaine number.
• Unexplained intra-operative hypercarbia + rigidity + tachycardia: malignant hyperthermia until proven otherwise.
• Tachycardia with a relaxant: pancuronium (vagolytic) or rocuronium (mild), vs hypotension with d-tubocurarine/atracurium (histamine).

Recently asked / exam angle

• "Earliest sign of malignant hyperthermia?" → rise in end-tidal CO₂; treatment → dantrolene; gene → RYR1.
• "Which NMBA is safe in both hepatic and renal failure?" → atracurium / cisatracurium (Hofmann elimination).
• "Drug of choice for rapid sequence intubation?" → succinylcholine; if contraindicated → high-dose rocuronium (reversible by sugammadex).
• "Sugammadex reverses which agent?" → rocuronium / vecuronium (NOT atracurium, NOT succinylcholine).
• "Dibucaine number 20 implies?" → atypical homozygous pseudocholinesterase → prolonged apnoea.
• "Neostigmine combined with which drug for reversal?" → glycopyrrolate.
• "Succinylcholine contraindicated in?" → burns, crush injury, denervation, hyperkalaemia, raised IOP (open globe).
• Phase II block: fade present, reversed by neostigmine — frequently paired against Phase I in match-the-following.
• "TOF ratio for safe extubation?" → > 0.9.
• Metabolite of atracurium causing seizures → laudanosine.

Rapid revision

1. Succinylcholine = fastest onset, shortest duration; depolarising; metabolised by plasma pseudocholinesterase.
2. Succinylcholine causes fasciculations, hyperkalaemia, MH, prolonged apnoea, raised IOP/ICP, bradycardia.
3. Phase I block: no fade, no post-tetanic potentiation, worsened by neostigmine.
4. Phase II block: fade present, reversed by neostigmine — resembles non-depolarising block.
5. Low dibucaine number (≈20) = atypical pseudocholinesterase = prolonged paralysis; manage with ventilation, not neostigmine.
6. Malignant hyperthermia: RYR1 gene, triggers = succinylcholine + volatiles, earliest sign = ↑ETCO₂, treat with dantrolene.
7. Atracurium / cisatracurium → Hofmann elimination → organ-independent → safe in hepatic & renal failure; atracurium → laudanosine (seizures).
8. Rocuronium = fastest-onset non-depolariser; pancuronium = vagolytic (tachycardia); tubocurarine = histamine + ganglion block (hypotension).
9. Non-depolarising block shows fade + post-tetanic potentiation; potentiated by aminoglycosides, Mg²⁺, inhalational agents; resisted with chronic phenytoin.
10. Reversal: neostigmine + glycopyrrolate (for non-depol, needs some recovery); sugammadex for rocuronium/vecuronium (even deep block).
11. Sugammadex does NOT reverse atracurium, cisatracurium, or succinylcholine.
12. TOF ratio > 0.9 = adequate recovery; diaphragm is last paralysed, first to recover; NMBAs are leading cause of peri-operative anaphylaxis.